Skip to content
2000
Volume 24, Issue 5
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Introduction

Glioblastoma (GB) is one of the deadliest human brain tumors. The prognosis is unfavorable, chemotherapy with temozolomide (TMZ) may extend the survival period for a patient. The paper aims to evaluate the survival rates among relapsing GB patients, who have been treated with valproic acid (VPA), and to study its effect on tumor cells when combined with TMZ and celecoxib (CXB).

Materials and Methods

The research is based on retrospective analysis of the data from GB patients who had been treated with VPA as a part of a complex treatment protocol and reoperated due to a GB relapse. The experimental study involved cancer cells of C6, U87, and T98G lines. GB was modeled on Wistar rats. The research was approved by the ethics committee. Differences in groups were considered significant at < 0.05

Results

The median of overall survival among GB patients who took VPA was 22 months, and for those who did not take VPA - 13 months. The experiment showed the half-maximal inhibitory concentration (IC) of TMZ for various lines of cancer cells (CCs) varying from 435.3 to 844 μM. IC VPA for CCs of U87MG, T98G, and С6 lines was 1510, 3900, and 3600 μM: IC CXB for those lines of CCs was 30.1 μM, 41.07, and 48.4 μM respectively. VPA significantly enhanced the anti-glioma effect of TMZ on the U87 line of CCs, while CCs of C6 and T98G lines proved to be most susceptible to the combination of CXB and TMZ. The combination of VPA with CXB increased the anti-glioma effect of TMZ both and , also reducing the tumor size ( < 0.05) and prolonging the survival period among experimental animals.

Conclusion

VPA and CXB enhance the effect of TMZ on glioblastoma cells.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273330268241008220702
2024-10-18
2025-09-01

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273330268241008220702
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McMahonD.J. GleesonJ.P. O’ReillyS. BamburyR.M. Management of newly diagnosed glioblastoma multiforme: Current state of the art and emerging therapeutic approaches.Med. Oncol.202239912910.1007/s12032‑022‑01708‑w 35716200
     [Google Scholar]
  2. ObradorE. Moreno-MurcianoP. Oriol-CaballoM. Glioblastoma therapy: Past, present and future.Int. J. Mol. Sci.2024255252910.3390/ijms25052529 38473776
     [Google Scholar]
  3. Vaz-SalgadoM.A. VillamayorM. AlbarránV. Recurrent Glioblastoma: A review of the treatment options.Cancers (Basel)20231517427910.3390/cancers15174279 37686553
     [Google Scholar]
  4. KarveA.S. DesaiJ.M. GadgilS.N. A review of approaches to potentiate the activity of temozolomide against glioblastoma to overcome resistance.Int. J. Mol. Sci.2024256321710.3390/ijms25063217 38542190
     [Google Scholar]
  5. ValeriusA.R. WebbL.M. SenerU. Novel clinical trials and approaches in the management of glioblastoma.Curr. Oncol. Rep.202426543946510.1007/s11912‑024‑01519‑4 38546941
     [Google Scholar]
  6. DrexlerR. KhatriR. SchüllerU. Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma.Acta Neuropathol.202414712110.1007/s00401‑023‑02677‑8 38244080
     [Google Scholar]
  7. TompaM. KajtarB. GalikB. GyeneseiA. KalmanB. DNA methylation and protein expression of Wnt pathway markers in progressive glioblastoma.Pathol. Res. Pract.202122215342910.1016/j.prp.2021.153429 33857857
     [Google Scholar]
  8. BerendsenS. FrijlinkE. KroonenJ. Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.Neurooncol. Adv.201911vdz02510.1093/noajnl/vdz025 32642660
     [Google Scholar]
  9. DamanskienėE. BalnytėI. ValančiūtėA. AlonsoM.M. StakišaitisD. Different effects of valproic acid on SLC12A2, SLC12A5 and SLC5A8 gene expression in pediatric glioblastoma cells as an approach to personalised therapy.Biomedicines202210596810.3390/biomedicines10050968 35625705
     [Google Scholar]
  10. TsaiH.C. WeiK.C. ChenP.Y. Valproic acid enhanced temozolomide-induced anticancer activity in human glioma through the p53-PUMA apoptosis pathway.Front. Oncol.20211172275410.3389/fonc.2021.722754 34660288
     [Google Scholar]
  11. DrzewieckaM. Gajos-MichniewiczA. HoserG. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.Genes (Basel)2023146129510.3390/genes14061295 37372475
     [Google Scholar]
  12. BarciszewskaA.M. BelterA. GawrońskaI. Giel-PietraszukM. Naskręt-BarciszewskaM.Z. Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines.Front. Oncol.202212103303510.3389/fonc.2022.1033035 36465345
     [Google Scholar]
  13. YinD. JinG. HeH. Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.Aging (Albany NY)20211317212682128210.18632/aging.203443 34497154
     [Google Scholar]
  14. LombardiF. AugelloF.R. ArtoneS. Involvement of cyclooxygenase-2 in establishing an immunosuppressive microenvironment in tumorspheres derived from TMZ-resistant glioblastoma cell lines and primary cultures.Cells202413325810.3390/cells13030258 38334650
     [Google Scholar]
  15. TanA.C. AshleyD.M. LópezG.Y. MalinzakM. FriedmanH.S. KhasrawM. Management of glioblastoma: State of the art and future directions.CA Cancer J. Clin.202070429931210.3322/caac.21613 32478924
     [Google Scholar]
  16. van den BentM.J. GeurtsM. FrenchP.J. Primary brain tumours in adults.Lancet2023402104121564157910.1016/S0140‑6736(23)01054‑1 37738997
     [Google Scholar]
  17. LeeP.Y. WeiY.T. ChaoK.S.C. ChuC.N. ChungW.H. WangT.H. Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study.J. Cancer Res. Ther.202420255556210.4103/jcrt.jcrt_750_22 38687925
     [Google Scholar]
  18. YoungbloodMW StuppR SonabendAM Role of resection in glioblastoma management.Neurosurg Clin N Am202132192210.1016/j.nec.2020.08.002 33223030
     [Google Scholar]
  19. ValiyaveettiD. MalikM. JosephD.M. AhmedS.F. KothwalS.A. VijayasaradhiM. Effect of valproic acid on survival in glioblastoma: A prospective single-arm study.South Asian J. Cancer20187315916210.4103/sajc.sajc_188_17 30112328
     [Google Scholar]
  20. WatanabeS. KuwabaraY. SuehiroS. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.Eur. J. Clin. Pharmacol.201773335736310.1007/s00228‑016‑2167‑1 27889835
     [Google Scholar]
  21. KastR.E. Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.Ann. Pharm. Fr.202179548148810.1016/j.pharma.2021.03.001 33689795
     [Google Scholar]
  22. RivaG. CilibrasiC. BazzoniR. Valproic acid inhibits proliferation and reduces invasiveness in glioma stem cells through Wnt/β catenin signalling activation.Genes (Basel)201891152210.3390/genes9110522 30373123
     [Google Scholar]
  23. MaS. GuoZ. WangB. A computational framework to identify biomarkers for glioma recurrence and potential drugs targeting them.Front. Genet.20221283262710.3389/fgene.2021.832627 35116059
     [Google Scholar]
  24. SahuU. BarthR.F. OtaniY. McCormackR. KaurB. Rat and mouse brain tumor models for experimental neuro-oncology research.J. Neuropathol. Exp. Neurol.202281531232910.1093/jnen/nlac021 35446393
     [Google Scholar]
  25. AllenM. BjerkeM. EdlundH. NelanderS. WestermarkB. Origin of the U87MG glioma cell line: Good news and bad news.Sci. Transl. Med.20168354354re310.1126/scitranslmed.aaf6853
     [Google Scholar]
  26. HuangZ. XiaY. HuK. Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.J. Neurochem.2020152222123410.1111/jnc.14849 31390677
     [Google Scholar]
  27. LiangS. WangX. PiaoM. Activated SIRT1 contributes to DPT-induced glioma cell parthanatos by upregulation of NOX2 and NAT10.Acta Pharmacol. Sin.202344102125213810.1038/s41401‑023‑01109‑3 37277492
     [Google Scholar]
  28. ChangH.H. ChangY.Y. TsaiB.C. A selective histone deacetylase inhibitor induces autophagy and cell death via SCNN1A downregulation in glioblastoma cells.Cancers (Basel)20221418453710.3390/cancers14184537 36139696
     [Google Scholar]
  29. TsaiC.Y. KoH.J. HuangC.Y.F. Ionizing radiation induces resistant glioblastoma stem-like cells by promoting autophagy via the Wnt/β-catenin pathway.Life (Basel)202111545110.3390/life11050451 34069945
     [Google Scholar]
  30. ZaitsevS. SharmaH.S. SharmaA. Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain.Int. Rev. Neurobiol.202015125327910.1016/bs.irn.2020.03.027 32448611
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273330268241008220702
Loading
Valproic Acid and Celecoxib Enhance the Effect of Temozolomide on Glioblastoma Cells
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 24, 375 (2025); https://doi.org/10.2174/0118715273330268241008220702
/content/journals/cnsnddt/10.2174/0118715273330268241008220702
/content/journals/cnsnddt/10.2174/0118715273330268241008220702
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): cancer stem cells; celecoxib (CXB); chemoradiation therapy (CRT); convulsive syndrome; Glioblastoma (GB); temozolomide (TMZ); valproic acid (VPA)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test